Q1 2026 Labcorp Holdings Inc Earnings Call Transcript
Key Points
- Labcorp Holdings Inc (LH) reported strong financial results for Q1 2026, with enterprise revenue reaching $3.5 billion, a 5.8% increase from the previous year.
- The Diagnostics segment saw a 5% revenue growth, driven by organic growth and acquisitions.
- The Biopharma Laboratory Services (BLS) segment experienced an 8% revenue increase, with Central Labs showing significant growth.
- Labcorp Holdings Inc (LH) continues to expand its strategic partnerships, including a nationwide collaboration with Children's Hospital of Philadelphia and acquisitions like Crouse Health Laboratory Alliance.
- The company is making significant advancements in specialty testing areas such as oncology, neurology, and autoimmune diseases, which are expected to grow faster than the broader diagnostics market.
- Adverse weather conditions impacted Q1 2026 results, with an estimated $15 million negative effect on the Diagnostics business.
- The potential impact of the ACA exchange changes remains uncertain, with a projected 30 basis point volume impact on Diagnostics for the year.
- The Early Development segment within BLS is relatively flat, with strategic actions still in progress.
- Reimbursement challenges persist in specialty testing areas like oncology, affecting pricing and margins.
- The impact of the PAMA survey and potential changes to reimbursement rates could affect Labcorp Holdings Inc (LH)'s financial performance, depending on hospital participation and data reporting.
Good day, and thank you for standing by. Welcome to the Q1 2026 Labcorp Holdings earnings conference call. (Operator Instructions)
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Dewey Steadman, Senior Vice President, Investor Relations. Please go ahead.
Thank you, Didi. Good morning, and welcome to Labcorp's first-quarter 2026 financial results webcast. With me today are Adam Schechter, our Chairman and Chief Executive Officer; and Julia Wang, our Executive Vice President and Chief Financial Officer.
This morning, in the Events section of the Labcorp Investor Relations website at ir.labcorp.com, we posted both our press release and a supplemental financial presentation with additional information on our business and operations. We will also host a replay of this webcast on the IR website for one year.
On today's webcast, we will focus on our adjusted non-GAAP results for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
